Leukodystrophies

Overview

Leukodystrophies are a diverse group of inherited disorders that damage the brain’s white matter—the nerve fibers and myelin insulation needed for efficient communication in the nervous system. They include conditions with very different genetic causes, ages of onset, and patterns of disease, such as metachromatic leukodystrophy (MLD), X-linked adrenoleukodystrophy (X-ALD), Krabbe disease, Canavan disease, Alexander disease, and vanishing white matter disease. Many begin in infancy or childhood, although some appear in adolescence or adulthood; severe early-onset forms can rapidly cause loss of movement, thinking, feeding, speech, vision, and breathing abilities and can be life-limiting. Leukodystrophies in Children

There is no single cure for “leukodystrophies” as a whole, because they are many distinct diseases. Standard care still includes genetic diagnosis, MRI monitoring, management of seizures and spasticity, nutritional and respiratory support, rehabilitation, and multidisciplinary palliative care when needed. For selected diseases and at very early stages, allogeneic hematopoietic stem-cell transplantation (HSCT)—transplantation of donor blood-forming stem cells—can slow neurologic injury, but it carries substantial risks and cannot reliably reverse damage that is already established. Recent Advancements in Diagnosis and Treatment

Scope of Recent Research (2020–present)

Research activity has accelerated markedly since 2020, particularly around treatments that address the underlying genetic defect before irreversible myelin and axonal injury occurs. The dominant questions are how to identify affected children early enough, deliver a therapeutic gene or RNA drug broadly enough in the brain and peripheral nerves, establish durable benefit, and reduce the risks of chemotherapy, transplantation, viral vectors, and immune responses. A 2024 review identified clinical gene-therapy programs across eight leukodystrophies, but only a small number have reached regulatory approval; thus, the field is entering an era of disease modification for selected subtypes rather than a general, established cure. Gene Therapy for the Leukodystrophies

Major Breakthroughs and Emerging Therapies

The clearest clinical breakthrough is ex vivo lentiviral gene therapy for enzyme-deficiency leukodystrophies. In this approach, clinicians collect a patient’s own blood-forming stem cells, insert a working copy of the missing gene using a lentiviral vector in the laboratory, and reinfuse the corrected cells after chemotherapy conditioning. In March 2024, the U.S. Food and Drug Administration (FDA) approved atidarsagene autotemcel, marketed as Lenmeldy, for children with presymptomatic late-infantile MLD, presymptomatic early-juvenile MLD, or early symptomatic early-juvenile MLD. In the supporting program, treated presymptomatic late-infantile children had substantially better severe-motor-impairment-free survival than untreated natural-history comparators; however, the treatment is not intended to restore neurologic abilities already lost. FDA approval of Lenmeldy Long-term atidarsagene results

A related stem-cell gene-therapy strategy is approved for a narrowly defined group with early, active cerebral X-ALD. Elivaldogene autotemcel, marketed as Skysona, supplies a functional copy of ABCD1 in autologous blood stem cells and is indicated in the United States for boys aged 4–17 years who lack an available HLA-matched donor for conventional HSCT. The therapy can slow neurologic progression in appropriately selected patients, but it does not treat adrenal insufficiency and now carries a prominent warning because myelodysplastic syndrome and acute myeloid leukemia have occurred after treatment; patients require long-term blood-count and clonal-expansion surveillance. Skysona FDA product page Skysona prescribing information

In vivo gene replacement—delivering a therapeutic gene directly to the central nervous system with an adeno-associated virus (AAV)—is progressing for diseases in which the key target cells are in the brain. In a 2025 open-label phase 1/2 Canavan disease study, eight children received intracranial rAAV-Olig001-ASPA (MYR-101), designed to target oligodendrocytes, the cells that make myelin. At 12 months, investigators reported reduced cerebrospinal-fluid N-acetylaspartate, increased MRI measures of myelination, and improved developmental scores; all serious adverse events resolved and were judged unrelated to treatment. These are promising early findings, not proof of a cure, because the trial was small, unblinded, and interim. Canavan phase 1/2 trial

RNA therapeutics are opening another path for leukodystrophies caused by toxic overproduction rather than a missing enzyme. Zilganersen is an antisense oligonucleotide—an RNA-like medicine intended to reduce production of glial fibrillary acidic protein (GFAP)—for Alexander disease. Ionis reported positive topline results from its 54-participant phase 1–3 study in September 2025, including stabilization of gait speed at week 61 in the 50-mg group; the evidence had not yet been published in a peer-reviewed paper as of August 8, 2026. The FDA accepted the new drug application for priority review, with an action date of September 22, 2026, so it remains investigational on the report date. Ionis topline Alexander disease results FDA orphan-drug status for zilganersen

Clinical Trials and Experimental Approaches

Notable current and recently reported programs illustrate the range of approaches. Lenmeldy’s pivotal evidence came from two open-label studies and expanded access, compared against untreated natural-history data rather than a randomized control group; FDA approval requires long-term monitoring for risks including thrombosis, encephalitis, delayed platelet recovery, and potential hematologic malignancy. In Europe, the same therapy is authorized as Libmeldy, and its long-term observational follow-up study is designed to assess durability and safety. FDA approval of Lenmeldy EMA Libmeldy overview

For infantile Krabbe disease, Forge Biologics sponsors the ongoing, non-randomized phase 1/2 RESKUE trial of FBX-101, a single intravenous AAVrh10 vector carrying the GALC gene, given after standard HSCT. The trial enrolls infants aged 1 day to 12 months and evaluates safety, transplant engraftment, sitting, and gross-motor development; public registry results were not posted at the time of this report. RESKUE trial: FBX-101 for Krabbe disease In Canavan disease, the phase 1/2 MYR-101 study has produced peer-reviewed interim results, while the separate CANaspire study of AAV9-based BBP-812 remains an experimental program without posted registry results. CANaspire trial: BBP-812

Precision programs are also reaching individual or ultra-small patient populations. A single-participant, personalized antisense-oligonucleotide study for autosomal-dominant leukodystrophy caused by an LMNB1 mutation is active but not recruiting, underscoring both the promise and the practical limits of tailored RNA medicines. Personalized ASO trial for LMNB1-related ADLD

Methodologies and Scientific Approaches

Researchers combine natural-history cohorts, newborn screening, genetic and biochemical confirmation, serial MRI, neurodevelopmental testing, and fluid biomarkers to determine whether a treatment has changed disease trajectory. In MLD, expert guidance emphasizes genetic plus biochemical diagnosis and supports newborn screening because treatment before symptoms is associated with better outcomes. In X-ALD, MRI surveillance is used to detect the early inflammatory cerebral stage in which HSCT or gene therapy is most likely to help. MLD monitoring and management guidelines X-ALD MRI surveillance guidelines

The therapeutic platforms differ by biology. Lentiviral stem-cell gene therapy is particularly suited to diseases in which corrected blood-derived cells can deliver a missing enzyme to the nervous system. AAV programs aim to directly transduce cells in the brain or body, with capsid selection and route of administration—intravenous, intrathecal, or intracranial delivery—chosen to reach the relevant tissue. RNA-targeted medicines such as antisense oligonucleotides instead reduce production of a harmful protein and can be repeatedly administered and adjusted, unlike a permanent gene insertion. Gene Therapy for the Leukodystrophies Canavan phase 1/2 trial

Leading Institutions and Funding

The San Raffaele–Telethon Institute for Gene Therapy (SR-Tiget) in Milan and Fondazione Telethon developed the hematopoietic stem-cell gene-therapy platform underlying MLD treatment; Orchard Therapeutics licensed and commercialized the therapy as Libmeldy and Lenmeldy. Bluebird bio developed Skysona for cerebral X-ALD, while University of Michigan/Michigan Medicine and Forge Biologics are central to the FBX-101 Krabbe program. Canavan programs involve institutions including Dayton Children’s Hospital, Rowan-Virtua, the University of Cincinnati, and Myrtelle, while Ionis leads the Alexander disease antisense program. Telethon authorized therapies Canavan phase 1/2 trial RESKUE trial: FBX-101 for Krabbe disease

Public and charitable funding remains important because many leukodystrophies affect very small populations and require costly natural-history studies and specialized manufacturing. For example, the California Institute for Regenerative Medicine awarded $7,377,384 for process development of an induced-pluripotent-stem-cell therapeutic candidate for Canavan disease, and the European Leukodystrophy Association awarded €159,589 for a two-year Canavan gene-therapy research project. CIRM Canavan disease grant listing ELA-supported Canavan research award

Strengths, Limitations, and Challenges

The major strength of recent work is that therapies can now address a root genetic cause rather than only symptoms. The strongest evidence comes from early treatment of MLD and cerebral X-ALD, where stem-cell gene therapy can alter the expected course of disease in selected patients. The central lesson is timing: myelin loss and axonal injury are often irreversible, so a biologically powerful therapy may still have limited benefit after substantial symptoms begin. FDA approval of Lenmeldy MLD monitoring and management guidelines

The limitations are substantial. Ex vivo therapies require intensive chemotherapy and specialized transplant centers; lentiviral integration can create a long-term cancer risk, as demonstrated by Skysona-associated hematologic malignancies. Direct AAV approaches must overcome immune barriers, dosing constraints, incomplete distribution throughout the brain and peripheral nerves, and the challenge of treating young children safely. Small patient numbers make randomized trials difficult, so developers often rely on natural-history comparators, which can introduce uncertainty. Access is also constrained by newborn-screening gaps, referral delays, manufacturing capacity, and the high cost of individualized advanced therapies. Skysona prescribing information FDA real-world-evidence approvals

Outlook and Future Directions

Leukodystrophy research is closer than ever to durable disease modification for several genetically defined disorders, but a broadly applicable cure is not imminent. The most important milestones to watch are expansion of newborn screening and rapid confirmatory diagnosis; long-term safety and durability data for Lenmeldy and Skysona; full results from AAV programs in Canavan and Krabbe disease; and the FDA’s scheduled September 22, 2026 decision on zilganersen for Alexander disease. Progress will depend on demonstrating that treatment preserves meaningful lifelong function, reaches the entire nervous system safely, and becomes available before irreversible injury occurs. Newborn screening for MLD review FDA priority-review date for zilganersen

References

• Leukodystrophies in Children — American Academy of Pediatrics, 2021.
• Recent Advancements in Diagnosis and Treatment — Bradbury and Ream, 2021.
• Gene Therapy for the Leukodystrophies — Kwon et al., 2024.
• FDA approval of Lenmeldy — U.S. Food and Drug Administration, 2024.
• Long-term atidarsagene results — Fumagalli et al., New England Journal of Medicine, 2025.
• Skysona FDA product page — U.S. Food and Drug Administration, 2025.
• Skysona prescribing information — bluebird bio and U.S. Food and Drug Administration, 2025.
• Canavan phase 1/2 trial — Leone et al., Nature Medicine, 2025.
• Ionis topline Alexander disease results — Ionis Pharmaceuticals, 2025.
• FDA orphan-drug status for zilganersen — U.S. Food and Drug Administration, 2026.
• EMA Libmeldy overview — European Medicines Agency, 2025.
• RESKUE trial: FBX-101 for Krabbe disease — ClinicalTrials.gov, 2026.
• CANaspire trial: BBP-812 — ClinicalTrials.gov, 2026.
• Personalized ASO trial for LMNB1-related ADLD — ClinicalTrials.gov, 2025.
• MLD monitoring and management guidelines — Adang et al., 2024.
• X-ALD MRI surveillance guidelines — Mallack et al., 2021.
• Telethon authorized therapies — Fondazione Telethon, 2026.
• CIRM Canavan disease grant listing — California Institute for Regenerative Medicine, 2026.
• ELA-supported Canavan research award — Alex – The Leukodystrophy Charity, 2024.
• FDA real-world-evidence approvals — U.S. Food and Drug Administration, 2026.
• Newborn screening for MLD review — Systematic literature review, 2025.
• FDA priority-review date for zilganersen — Drugs.com, 2026.